Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.0152W HIGH $15.04
Volume
730.74 K
Value Traded
9.04 M
Short % Float
9.79%
+6.45%Week
-5.16%1 Month
-13.58%3 Month
+17.18%6 Month
+0.4%5 Year
-94.66%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
676.38 M
EPS (TTM)
0.98
P/E Ratio
11.61
Ent. Value
416.20 M
Total Shares
59.38 M
Float Shares
58.63 M
Insiders
1.27%
Institutions
76.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ZVRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Zevra Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zevra Therapeutics, Inc.
261Total events
1Upcoming
79Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 1
TBD
T1CHMP Negative Opinion
Subscribe to view catalyst details
Event history 50
◆Poster PresentationMIPLYFFAApprovedPresentation
Presentation of two posters featuring long-term real-world data on MIPLYFFA at SSIEM Annual Symposium
Niemann-Pick disease type C (NPC)source ↗
●PublicationarimoclomolApprovedPresentation
Long-term real-world safety and effectiveness of arimoclomol in NPC: Outcomes from US early access program published
Niemann-Pick disease type C (NPC)source ↗
●RWE DataMIPLYFFAApprovedClinical Data
Publication of four-year real-world data from US Early Access Program
Niemann-Pick disease type C (NPC)source ↗
▼CHMP Negative OpinionarimoclomolApprovedEx-US Regulatory
CHMP adopted negative opinion for arimoclomol MAA
Niemann-Pick disease type C (NPC)source ↗
▲PublicationMIPLYFFAApprovedPresentation
Publication of arimoclomol pediatric substudy results in Molecular Genetics and Metabolism Reports
Niemann-Pick disease type C (NPC)source ↗
◆EU MAA SubmissionarimoclomolApprovedEx-US Regulatory
MAA under review by EMA for arimoclomol in NPC
Niemann-Pick disease type Csource ↗
●Enrollment UpdateceliprololTrial
Enrolled 10 patients in Q1 2026, total 62 in Phase 3 DiSCOVER trial
Vascular Ehlers-Danlos Syndromesource ↗
▲Partnership / LicenseCorporate
Zevra sells SDX portfolio (AZSTARYS and KP1077) to Commave Therapeutics for $50 million
▲IP Litigation RulingIP / Competition
Zevra and Commave settle Delaware Chancery Court litigation
●Poster PresentationarimoclomolApprovedPresentation
Poster presentation at Annual Clinical Genetics Meeting on March 13, 2026
Niemann-Pick disease type Csource ↗
●Type C MeetingarimoclomolApprovedFDA Meeting
Engaged FDA in Type C meeting to discuss regulatory options to accelerate development
Vascular Ehlers-Danlos Syndromesource ↗
●EU MAA SubmissionarimoclomolApprovedEx-US Regulatory
MAA for arimoclomol under EMA review; 120-day list of questions received
Niemann-Pick disease type Csource ↗
●Enrollment UpdatearimoclomolApprovedTrial
Enrolled 8 patients in Q4 2025, total 52 patients in Phase 3 DiSCOVER trial
Vascular Ehlers-Danlos Syndromesource ↗
▲EMA ValidationarimoclomolApprovedEx-US Regulatory
EMA validated Marketing Authorisation Application for arimoclomol
Niemann-Pick disease type Csource ↗
▲EU Orphan DesignationarimoclomolApprovedEx-US Regulatory
EMA Orphan Medicinal Product designation for arimoclomol
Niemann-Pick disease type Csource ↗
▲PublicationMIPLYFFAApprovedPresentation
OLE data showing sustained long-term efficacy published in Molecular Genetics and Metabolism
Niemann-Pick disease type Csource ↗
●Enrollment UpdateceliprololTrial
Enrolled 5 patients in Q3 2025, total 44 patients in DiSCOVER trial
Vascular Ehlers-Danlos Syndromesource ↗
●Oral PresentationMIPLYFFAApprovedPresentation
Data presented at NNPDF, SERGG, ICIEM, INPDA, CNS conferences
Niemann-Pick disease type Csource ↗
●Poster PresentationMIPLYFFAApprovedPresentation
Poster on MIPLYFFA mechanism nominated for Best Poster Award
Niemann-Pick disease type Csource ↗
●EU MAA SubmissionarimoclomolApprovedEx-US Regulatory
Submitted MAA to EMA for arimoclomol for NPC
Niemann-Pick Disease Type Csource ↗
▲PRV SoldDesignation
Sale of Rare Pediatric Disease Priority Review Voucher for $150 million closed
●Enrollment UpdateceliprololTrial
Enrolled 7 patients in Phase 3 DiSCOVER trial of celiprolol in Q2 2025, total 39
Vascular Ehlers-Danlos Syndromesource ↗
●Enrollment UpdateMIPLYFFAApprovedTrial
7 prescription enrollment forms for MIPLYFFA in Q2 2025, total 129 since launch
Niemann-Pick disease type Csource ↗
●Enrollment UpdateOLPRUVAApprovedTrial
1 prescription enrollment form for OLPRUVA in Q2 2025, total 29 since launch
Urea Cycle Disorderssource ↗
●Quarterly UpdateCorporate
Preliminary unaudited cash, cash equivalents and investments as of March 31, 2025
▲PRV SoldDesignation
Zevra enters agreement to sell Rare Pediatric Disease Priority Review Voucher for $150 million
▲FDA ApprovalMIPLYFFAApprovedFDA Decision
FDA approval of MIPLYFFA for NPC
Niemann-Pick disease type C (NPC)source ↗
▲PRV GrantedMIPLYFFAApprovedDesignation
PRV granted to Zevra following MIPLYFFA approval
Niemann-Pick disease type Csource ↗
▼Equity OfferingCorporate
Registered direct offering of common stock and warrants to healthcare-focused investment fund
●Timing GuidancearimoclomolApprovedPresentation
NDA resubmission for arimoclomol in NPC expected as early as Q1 2023
Niemann-Pick disease type C (NPC)source ↗
▲FDA ApprovalOLPRUVAApprovedFDA Decision
FDA approval of OLPRUVA for UCDs
urea cycle disorders (UCDs)source ↗
Past FDA Catalysts and PDUFA Decisions
How ZVRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-10-10 | Olpruva (sodium phenylbutyrate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$232M
Pipeline Value
$323M
Commercial Value
Fair Value
Valuation Signal
4
Drugs Scored
0.7x
rNPV / MCap
Top 46%
Micro Cap(rank 304 of 660)
Percentile Rank
Zevra Therapeutics, Inc. faces pipeline headwinds (38/100), with $579M risk-adjusted pipeline value, led by ACER-002 in Vascular Ehlers-Danlos Syndrome (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $136.1M x 2.4 = $323M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| MIPLYFFA | $104M | $49M | +112.9% |
| OLPRUVA | $1M | $1M | +80% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ACER-002 Small moleculeNCT05432466 | Vascular Ehlers-Danlos Syndrome | Phase 3 | RECRUITING | 150 | Apr 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every ZVRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MIPLYFFA PriorityOrphanRare Pediatric | Niemann-Pick disease type C | 2026-08-25 | Durable disease stabilization through 4 years: minimal changes in disease severity over time, scores remained essentially unchanged from baseline at year 1 (11.2 vs. 11.1; n=78) and year 4 (11.6 vs. 11.6; n=20); Consistent stabilization across age groups: at year 3, scores remained stable in children (10.7 vs. 10.8; n=16) and adults (10.7 vs. 10.2; n=22); Sustained stabilization in children: among children ages 2 · 19 receiving arimoclomol plus miglustat, scores remained stable at year 1 (9.7 vs. 9.1; n=27) and year 4 (10.0 vs. 10.3; n=4); Pivotal trial showed a 65% reduction in disease progression: average disease severity scores increased by 0.76 with arimoclomol vs. 2.15 with placebo over 12 months; Long-term treatment experience of up to 8 years: 48 people with NPC received arimoclomol and mean treatment exposure of 3.0 years; 46 (95.8%) received arimoclomol plus miglustatRead More | Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual SymposiumRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Thompson RahsaanOfficer (Chief Legal & Compliance) | Sell | -42,666 37,569 held | $11.13 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZVRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ZVRA for Q2 2026. | ||||
ZVRA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZVRA ranks across every disease it competes in
Competitive Position is a premium feature
See how ZVRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZVRA News
ZVRAZevra Therapeutics to Present at Upcoming Investor Conferences
Zevra Therapeutics, Inc. announced that its executive leadership will present at several upcoming investor conferences in New York. The presentations include fireside chats at the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. Management will also be available for one-on-one meetings with attendees.
Read more →ZVRAZevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Zevra Therapeutics announced the presentation of new long-term real-world data on MIPLYFFA (arimoclomol) for Niemann-Pick disease type C at the SSIEM Annual Symposium. The data demonstrates sustained disease stabilization over four years, with no treatment-related discontinuations. The findings underscore the therapy's effectiveness and safety, providing insights from up to eight years of treatment experience.
Read more →ZVRAZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics announced the granting of options to purchase 92,200 shares to four new employees under its 2023 Employment Inducement Award Plan. These awards, approved by the Compensation Committee, vest over four years and are part of the company's strategy to attract talent. Zevra focuses on developing therapies for rare diseases, including Niemann-Pick disease type C.
Read more →ZVRA▲ +12.8%on this news
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
Zevra reported a net revenue of $39.7 million for Q2 2026, marking a 53% increase from the previous year. The revenue growth was primarily driven by $30.2 million from MIPLYFFA. The company also highlighted a robust cash position of $260.2 million. A conference call is scheduled for August 5, 2026, to discuss these results.
Read more →ZVRAZevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics will present at the Canaccord Genuity Annual Growth Conference on August 11, 2026. The executive team will also hold one-on-one meetings with attendees. The company is dedicated to providing therapies for rare diseases and has a commercialized product for Niemann-Pick disease type C.
Read more →ZVRA▲ +5.7%on this news· ran to +25% by day 3shared move
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Zevra Therapeutics has published a four-year study on the real-world safety and effectiveness of arimoclomol for Niemann-Pick Disease Type C (NPC). The study, which included a diverse population of 109 participants, demonstrated stable disease severity scores and provided valuable insights into the management of NPC. MIPLYFFA, the company's approved therapy, has shown promising long-term clinical outcomes.
Read more →ZVRA▼ -23.9%on this news
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Zevra Therapeutics announced a negative opinion from the CHMP regarding its Marketing Authorization Application for arimoclomol to treat Niemann-Pick disease type C. The company plans to request a re-examination of this decision and continues to support patient access through its Expanded Access Program. Despite the setback, Zevra remains confident in the potential of arimoclomol.
Read more →ZVRAZevra Therapeutics Announces Details for Q2 2026 Financial Results Call
Zevra Therapeutics announced it will report its Q2 2026 financial results on August 5, 2026. The report will be followed by a conference call at 4:30 p.m. ET. Investors can access the call via a webcast or telephone, with a replay available for 90 days. The company focuses on therapeutics for rare diseases, particularly Niemann-Pick disease.
Read more →ZVRAZevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
Zevra Therapeutics announced the publication of positive data from a pediatric substudy evaluating arimoclomol for Niemann-Pick disease type C (NPC) in infants. The study demonstrated that arimoclomol was generally well tolerated and provided preliminary evidence supporting its use in this age group. The findings contribute to the growing body of evidence for MIPLYFFA's effectiveness across different ages.
Read more →ZVRAZevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
Zevra Therapeutics announced that its Chief Medical Officer, Dr. Adrian Quartel, will step down for personal reasons effective July 3, 2026. He will continue to support the company in a consulting role until the end of the year. The CEO expressed gratitude for Dr. Quartel's contributions, highlighting the company's ongoing regulatory milestones and clinical trials.
Read more →ZVRAZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 29, 2026
Zevra Therapeutics has granted options to purchase 33,000 shares of common stock to four new employees as part of its 2023 Employment Inducement Award Plan. Each award vests over four years, with the first 25% vesting after one year. This move aligns with Nasdaq Rule 5635(c)(4) and reflects the company's commitment to attracting talent while focusing on rare disease therapeutics.
Read more →ZVRAZevra Reports First Quarter 2026 Financial Results and Corporate Update
Zevra Therapeutics reported a 78% increase in net revenue for Q1 2026, totaling $36.2 million. The company completed a $50 million sale of its SDX portfolio, enhancing its financial stability. MIPLYFFA, its therapy for Niemann-Pick disease type C, continues to show strong performance. A conference call is scheduled for further updates.
Read more →ZVRAZevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - March 20, 2026
Zevra Therapeutics has granted an equity inducement award to its new CFO, Justin Renz, as part of its 2023 Employment Inducement Award Plan. The award includes an option to purchase 300,000 shares at $9.55, vesting over four years. This move aligns with Nasdaq Rule 5635(c)(4) and reflects the company's strategy to attract top talent.
Read more →ZVRAZevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million Companies Resolve Lawsuit in Delaware
Zevra Therapeutics has entered into a $50 million agreement with Commave Therapeutics for the sale of its serdexmethylphenidate portfolio, which includes the products AZSTARYS and KP1077. This transaction resolves a previous lawsuit initiated by Commave in 2024 against Zevra, highlighting a successful negotiation between the two companies. As part of the agreement, Zevra has also repaid a significant term loan, resulting in a debt-free status that enhances its financial flexibility. The company plans to continue its focus on rare diseases, reaffirming its commitment to patient-centric innovations.
Read more →ZVRAZevra Reports Fourth Quarter and Full Year 2025 Financial Results
Zevra Therapeutics, Inc. reported a robust financial performance for the fourth quarter and full year of 2025, highlighting a net revenue of $34.1 million for Q4, representing a 31% quarter-over-quarter growth. The company's total FY 2025 net revenue reached $106.5 million, primarily driven by strong sales of MIPLYFFA, which generated $87.4 million. The firm has also made strategic advancements in its operations, including relocating its headquarters to Boston and broadening access to its therapies through various programs. This positive trajectory reflects the company’s focus on addressing the needs of patients with rare diseases and creating shareholder value.
Read more →ZVRAZevra Therapeutics Appoints Justin Renz as Chief Financial Officer
Zevra Therapeutics has appointed Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz brings over 25 years of experience in the biopharmaceutical industry, having held key financial roles at various companies. His expertise is expected to enhance Zevra's strategic growth in providing therapies for rare diseases.
Read more →ZVRAZevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
Zevra Therapeutics, Inc. will report its Q4 and full year 2025 financial results on March 9, 2026. The company will host a conference call at 4:30 p.m. ET, with a link to the audio webcast available on its website. Zevra focuses on therapies for rare diseases and is expanding its product access.
Read more →ZVRAZevra Therapeutics to Present at the Citizens Life Sciences Conference
Zevra Therapeutics, Inc. will present at the Citizens Life Sciences Conference on March 11, 2026. The executive team will be available for one-on-one meetings with attendees. Zevra focuses on therapies for rare diseases, with a strong emphasis on its lead product for Niemann-Pick disease type C.
Read more →ZVRATranspire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
Transpire Bio Inc. has appointed R. LaDuane Clifton as Chief Financial Officer to enhance its leadership as it transitions from clinical to commercial stages. Clifton brings a wealth of experience in public finance and biopharmaceutical development. His appointment is seen as a strategic move to support the company's growth and corporate priorities.
Read more →About Zevra Therapeutics, Inc.
Headquarters101 FEDERAL STREET, BOSTON, MA, 02110
BIOPHARMAWATCH ELITE PLUS
Trade the next ZVRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime